Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9208MR)

This product GTTS-WQ9208MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9208MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8534MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Hu5A8
GTTS-WQ5065MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CaCP-29
GTTS-WQ6182MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CP-870893
GTTS-WQ13091MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-03446962
GTTS-WQ1203MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABP 980
GTTS-WQ8556MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ14037MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aLAG367
GTTS-WQ11MR IVTScrip™ mRNA-Anti-S, 2130(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 2130
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW